Q-omics provides the consensus-scored CWC25 profile across patient tissues and cancer cell-line models. CWC25 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CWC25 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, CWC25 protein abundance shows 20,329 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where CWC25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CWC25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CWC25 survival associations across molecular data types. CWC25 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CWC25 RNA expression–survival associations across cancer types. High CWC25 expression shows unfavorable associations in OV, UVM, LIHC and LGG, but favorable associations in KIRC and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for CWC25 RNA expression.
This table summarizes CWC25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CWC25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CWC25 shows lower tumor expression in THCA and KICH and higher tumor expression in KIRC, KIRP, HNSC and STAD. The KIRC box plot shows higher CWC25 RNA expression in tumor versus normal tissue (log2 FC = +0.498, t-test p < 0.001).
This table shows molecular features associated with CWC25 in patient tissues and cancer cell lines. In patient samples, CWC25 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CWC25 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
